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Prophylactic radiotherapy in retinoblastoma - is it really new?
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The concept of whole retina radiotherapy for infants and
youngsters with retinoblastoma is not new. Such treatment
was pioneered in the early 1960's shortly after the linear
accelerator became available for medical use (Bagshaw &
Kaplan, 1966). The linear accelerator provided the possibility
of using focused small field megavoltage radiation beams to
treat the entire retina while simultaneously sparing nearby
critical normal structures. This external beam radiotherapy
provided the delivery of a homogeneous dose distribution
across the area of interest, the entire retina. Such treatment
was immediately seen as an advantage over the use of even
more focal radiation as delivered using a radioactive cobalt
plaque (Stallard, 1968). While the brachytherapy plaque tech-
nique delivered extraordinarily high doses of radiation to the
area under the plaque, with a rapid fall off in dose so that
points within millimeters of the plaque were calculated to
receive almost negligible doses, it is of limited application
when the entire retina is at risk of developing disease, as in
the case in heritable retinoblastoma.
Most radiation oncologists have chosen to use a single
lateral radiation field for unilateral retinoblastoma and
bilateral opposed fields for bilateral retinoblastoma. However
the investigators at Utrecht, the Netherlands and those at St
Bartholomew's Hospital in London have employed a techni-
que to spare the contralateral eye by using beams angled
obliquely in a cranio-caudal or caudo-cranial direction
(Harnett et al., 1987a,b; Schipper, 1983). These obliqued
beams have been criticised because the radiation beam exits
through the opposite frontal lobe of the brain or the opposite
mandible and developing teeth, thus exposing these normal
developing structures to unnecessary radiation. By contrast a
single direct lateral megavoltage radiation beam of 4-6 MV,
calculated to 3 cm depth ensures that the ipsilateral eye lies
within the 90% isodose curve, whereas, the retina of the
opposite eye receives approximately 70% of the delivered
dose (Donaldson et al., 1993).
What is new is that Plowman et al. have utilised this direct
lateral technique in the treatment of an infant at high risk to
develop contralateral disease, and have demonstrated the
ability to prevent disease by this 'prophylactic' radiation
field. Using a direct lateral beam in a prophylactic fashion, in
a patient with heritable disease, assumes that subclinical
disease can be controlled with lower radiation doses than
that used for patients with gross disease. Dose response data
have been hard to obtain in retinoblastoma because only
narrow radiation doses have been used. In general, total
doses of 4,000 to 5,400 cGy in 3.5 to 6 weeks have been used
(Egbert et al., 1978; Harnett et al., 1987a; Schipper et al.,
1985). Recently, doses in the range of 2,100-4,400 cGy
(median dose 3,500 cGy) have been shown to be effective for
infants less than 1 year, suggesting that even lower doses may
be adequate for early stage disease (Fontanesi et al., 1992).
The concept of preventing tumours in the contralateral eye
by using bilateral treatment for infants with hereditary
retinoblastoma is more than justified when quality of vision
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is used to measure outcome. The likelihood of useful visual
acuity following radiation is the greatest when a uniform
homogenous dose is given. Visual acuities of 20/20 and 20/30
have been reported at long term follow-up in children who
had Reese-Ellsworth group I, II and III disease and were
treated with external beam radiotherapy (Egbert et al., 1978).
In this issue Plowman describes the therapeutic success rate
using the St Bartholomew's lens sparing technique in 44
children representing 55 treated eyes. Of the 18 failures, five
were true local recurrences and 13 were new tumours, 12 of
which developed at or anterior to the equator. This suggests
that the lens sparing technique as utilised may have provided
too generous a coverage to the anterior structures. However,
this technique designed by (Schipper et al., 1983) and
confirmed by Harnett and Plowman (Harnett et al., 1987a,b)
does provide a technical innovation into administration of
more precise localised radiation. However, equally good
dosimetry can be obtained by using a single or opposed
cerrobend shaped fields using a been splitting technique
where the central axis of the radiation beam is centered at
the ora serrata and all structures anterior to the ora serrata
are blocked using double thickness lead blocks (Donaldson et
al., 1993). The lens can be visualised by using a radio-opaque
contact lens marker. When treating infants in this fashion
one needs to rely upon good pediatric anaesthesia and
patient immobilisation. Treatment fields should be verified by
the radiation oncologist as well as the ophthalmologist at the
time of simulation and routinely therafter by the treating
radiation oncologist. Both techniques rely on adjuvant
cryotherapy for small ora serrata relapses and both techni-
ques have provided an excellent quality of vision (Egbert et
al., 1978, Schipper et al., 1985).
Recently, there has been increased interest in plaque
therapy for retinoblastoma, in part due to the concerns of
radiation induced cancers among these children who are
irradiated for heritable disease. However, the discovery of the
retinoblastoma gene at the 13q14 region has now provided
an understanding between the association of retinoblastoma
and other second malignant tumours, particularly osterosar-
coma. Mutational inactivation of retinoblastoma is found not
only in retinoblastoma but also in other cancers such as
osteosarcoma and other soft tissue sarcomas as well as breast
cancer, confirming that the secondary tumours are genetically
determined (Lee-Brookstein & Lee-WH-P, 1990). Thus, the
second malignant tumours are now recognised to be more
related to the inactivation of the retinoblastoma gene, rather
than to the treatment used to eradicate the retinoblastoma.
Furthermore, clinical experience has demonstrated that a
significant portion of these second malignant tumours occur
in areas outside of a radiation field or in children who have
never been exposed to radiation (Abramson et al., 1984).
The concern regarding second malignant tumours in child-
ren with heritable retinoblastoma will exist irrespective of the
treatment used. The extraordinarily large clinical experience
from the Moorfield Eye Institute in London coupled with the
progressive technical advances from the St Bartholomew's
radiotherapy group, makes this team unique in continuing to
refine the treatment of retinoblastoma in infants and young-
sters.
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